Directory

Dr Cook grew up in Kenya and studied medicine at St Bartholomew’s in London. He did a PhD at the National Heart and Lung Institute, UK and a Postdoctoral Fellowship at Harvard. He is a Group Head at the MRC London Institute of Medical Sciences and Professor at Imperial College, London and Duke-National University of Singapore (Duke-NUS). He was the founding Director of the National Heart Research Institute Singapore and Director of the CVMD program at Duke-NUS. His work on genetic heart muscle disease led to a new diagnostic test for inherited cardiac conditions that was commercialised by Illumina and resulted in new clinical genetics services in both the UK and Singapore. His group identified IL11 as a pro-fibrotic factor in 2017 and went on to define a key role for IL11 in a range of fibroinflammatory diseases. He is a co-founder of Enleofen Bio, a biotechnology company developing anti-fibrotic therapies that partnered with Boehringer Ingelheim in 2019, and of VVB Bio. The current focus of his research groups is on identifying new biology and targets for healthspan, genetic diseases, sepsis and cardiorenal conditions.